Glial cytoplasmic inclusions (GCIs) represent the defining pathological hallmark of Multiple System Atrophy (MSA), distinguishing it from other α-synucleinopathies like Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Unlike PD/DLB where α-synuclein aggregates primarily in neurons, MSA features predominant α-synuclein pathology in oligodendrocytes—the myelin-producing cells that support axons in the central nervous system. This oligodendroglial α-synucleinopathy underlies the rapidly progressive nature of MSA and its poor therapeutic response. [@pr漫步2022][@aoki2023]
GCIs are silver-positive, eosinophilic inclusions composed primarily of aggregated α-synuclein filaments co-assembled with phosphorylated α-synuclein, tau, and other neurodegenerative-associated proteins including p25α (TPPP/p25α), a brain-specific phosphoprotein enriched in oligodendrocytes. The sequential model of GCI formation involves:
- α-Synuclein overexpression in oligodendrocytes driven by dysregulated SNCA expression
- Misfolding and nucleation of α-synuclein into oligomeric intermediates
- Filament assembly into phosphorylated τ-positive fibrils
- GCI maturation with recruitment of myelin proteins and cytoskeletal elements
- Oligodendrocyte dysfunction leading to myelin maintenance failure
flowchart TD
A["Oligodendrocyte SNCA<br/>Overexpression"] --> B["α-Syn Misfolding"]
B --> C["Oligomer Formation"]
C --> D["Filament Assembly<br/>Phosphorylated α-Syn"]
D --> E["p25α Recruitment"]
E --> F["Tau Co-aggregation"]
F --> G["GCI Maturation"]
G --> H["Myelin Gene Dysregulation"]
H --> I["Oligodendrocyte Dysfunction"]
I --> J["Demyelination"]
J --> K["Axonal Degeneration"]
K --> L["Neuronal Death"]
The targeting of oligodendrocytes rather than neurons in MSA reflects several oligodendrocyte-specific factors:
| Factor |
Role in GCI Pathogenesis |
Reference |
| p25α/TPPP |
Key GCI component; regulates microtubule dynamics |
[@aoki2023] |
| MBP |
Myelin Basic Protein; recruited to GCIs |
[@martens2022] |
| PLP1 |
Proteolipid Protein 1; lipid metabolism |
[@martens2022] |
| CNP |
2',3'-Cyclic Nucleotide 3'-Phosphodiesterase |
[@valera2021] |
| MAG |
Myelin-Associated Glycoprotein |
[@valera2021] |
While SNCA point mutations cause familial PD, duplications and triplications of the SNCA gene have been linked to MSA cases, supporting a dose-dependent relationship between α-synuclein expression and oligodendrocyte pathology. [@kiyosawa2019] Studies show:
- SNCA duplication carriers: Develop MSA phenotype with prominent GCI pathology
- SNCA triplication carriers: Earlier onset and more severe disease
- SNCA expression in oligodendrocytes: Driven by oligodendrocyte-specific promoters (PLP1, MBP)
Multiple mechanisms drive SNCA overexpression in MSA oligodendrocytes:
- Epigenetic changes: Decreased DNA methylation at SNCA promoter
- Transcription factor dysregulation: Aberrant Olig1/2 activity
- mRNA stability: Increased SNCA mRNA half-life
- Non-coding RNAs: Dysregulated miRNAs targeting SNCA
MSA demonstrates selective vulnerability in specific brain regions, correlating with clinical subtypes:
- Affected regions: Putamen, caudate, substantia nigra pars compacta
- Pathology: Severe GCI burden, neuronal loss, iron deposition
- Clinical correlation: Parkinsonian features (bradykinesia, rigidity)
- Mechanism: Dopaminergic neuron loss secondary to oligodendrocyte failure
- Affected regions: Inferior olive, pons, cerebellar white matter
- Pathology: GCI-mediated demyelination, Purkinje cell loss
- Clinical correlation: Cerebellar ataxia, gait disturbance
- Mechanism: Disruption of olivocerebellar projections
- Affected regions: Nucleus tractus solitarius, dorsal motor nucleus of vagus, Onuf's nucleus
- Pathology: Variable GCI burden with neuronal loss
- Clinical correlation: Orthostatic hypotension, urinary dysfunction, erectile dysfunction
- Mechanism: Autonomic regulatory center dysfunction
A subset of MSA cases show co-pathology with tau protein, particularly in regions with high GCI burden:
- Mixed pathology: 20-30% of MSA cases show significant tau pathology
- Tau isoforms: Predominantly 4-repeat tau (4R-tau)
- Pattern: Tau-positive inclusions in neurons adjacent to GCI-rich regions
- Clinical impact: May accelerate disease progression
- LRRK2 G2019S carriers: May develop MSA phenotype
- Pathological features: Typical GCI pathology with LRRK2 positivity
- Implication: LRK2 inhibitors may have therapeutic potential
Multiple strategies targeting α-synuclein aggregation are in development:
| Approach |
Stage |
Mechanism |
Reference |
| Immunotherapy (ABBV-080) |
Phase 1/2 |
Anti-α-syn antibodies |
[@song2024] |
| Small molecule aggregation inhibitors |
Preclinical |
Block oligomerization |
[@song2024] |
| Gene therapy (SNCA silencing) |
Preclinical |
RNAi/ASO |
[@song2024] |
Oligodendrocyte function depends critically on cAMP signaling:
- Phosphodiesterase inhibitors: Increase cAMP to support oligodendrocyte survival
- Adenylyl cyclase agonists: Activate cAMP pathway
- Rolipram: PDE4 inhibitor showing preclinical promise
| Trial |
Intervention |
Phase |
Status |
| NCT03533038 |
Saroglitazar |
Phase 2 |
Completed |
| NCT04182885 |
ABBV-080 |
Phase 1 |
Active |
| NCT04269642 |
CoQ10 |
Phase 3 |
Recruiting |
| NCT04065014 |
Rifampin |
Phase 2 |
Completed |
- GDNF delivery: AAV-GDNF in preclinical models
- BDNF: Supporting oligodendrocyte survival
- MBP rescue agents: Targeting myelin maintenance
- Prange et al., Clinical correlates of GCI in MSA (2022)
- Aoki et al., Oligodendroglial alpha-synucleinopathy in MSA (2023)
- Song et al., Targeting alpha-synuclein aggregation in MSA (2024)
- Martens et al., Myelin protein genes in MSA (2022)
- Kiyosawa et al., SNCA multiplication in MSA (2019)
- Valera et al., Oligodendrocyte dysfunction in alpha-synucleinopathies (2021)
- Peng et al., Regional vulnerability in MSA (2018)
- Krismer et al., Neurofilament light chain as biomarker (2020)
- Singer et al., CoQ10 in MSA RCT (2021)